BSEInsider Trading / SAST2d ago · 30 Sept 2026, 05:16 pm
Intimation of Closure of Trading Window
Evoq Remedies Ltd · 543500
✦ AI Summary
Evoq Remedies Ltd has announced the closure of its trading window for all directors, promoters, designated persons, and insiders from October 1, 2026, until 48 hours after the declaration and publication of unaudited financial results for the half year ended September 30, 2026.
Analysis Scores
Earnings Impact5/10
Growth Catalyst5/10
Governance Concern5/10
Regulatory Risk5/10
Balance Sheet Risk5/10
Liquidity Impact5/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Evoq Remedies Ltd - 543500 - Closure of Trading Window
Attachments (1)
📄pdf
Download →
3fbcb0e1-b988-4aaf-ad47-f32d69fc24a5.pdf
View document text
Evoq Remedies Limited
CIN: L46209GJ2010PLC059692
Regd. Office: A-1106, Empire Business Hub Near AUDA Water Tank, Science City
Road, Sola Ahmedabad, Gujarat, India – 380 060
E-mail: evoqremedies@gmail.com Website: www.evoqremedies.com
Date: 30th September, 2026
BSE Limited
Phiroze Jeejeebhoy Tower,
Dalal Street,
Mumbai – 400 001
Dear Sir / Ma’am,
Subject: Intimation of Closure of Trading Window
Ref: Security Id: EVOQ / Code: 543500
Pursuant to Clause 4 of Schedule B of Securities and Exchange Board of India (Prohibition of Insider
Trading) Regulations, 2015 as amended and trading restrictions placed by the Company's Code of
Practices, Procedure and Conduct to Regulate, Monitor and Report Trading by Insiders (‘the Code’), we
hereby inform that the Trading Window for purchasing, selling or dealing in the Equity Shares of the
Company, will remain closed for all Directors, Promoters, Designated Persons and Insiders of the
Company from Thursday, 1st October, 2026 till 48 hours after the declaration and publication of
Unaudited Financial Results for the Half Year ended on 30th September, 2026.
Please take note of the same and oblige.
Thanking You.
For, Evoq Remedies Limited
Dipti Narayan Mundra
Resolution Professional
IBBI/IPA-001/IP-P-02845/2023-2024/14366